STAT October 9, 2024
FDA’s Tala Fakhouri says the agency has so far received nearly 500 submissions with AI components
In the last year, pharma incumbents have leaned into partnerships with AI-driven startups to supercharge drug discovery efforts. High-powered models of protein structure and molecule binding can help identify new disease targets, and even help design new drugs. But AI-derived or not, a new drug candidate still has to wind its way through the painstaking clinical trial process. That is why the pharma industry is also leaning into AI as a tool to...
Today's Sponsors
Today's Sponsor